Clinical Trial Update: Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating everolimus with or without bevacizumab in advanced kidney cancer that progressed after first-line therapy was terminated; results hav…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma
• Renal Cell Carcinoma

Drugs mentioned

• Bevacizumab (bevacizumab)
• Everolimus (everolimus)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma | Phase 3 | Status: TERMINATED | Results posted: 2019-03-06